InflaRx Commences Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe
May 14, 2019 08:00 ET
|
InflaRx N.V.
JENA, Germany, May 14, 2019 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today...
InflaRx Full Year 2018 Financial & Operating Results
March 28, 2019 08:30 ET
|
InflaRx N.V.
$62.9 million (€53.0 million) raised in a follow-on offering to advance clinical programs for IFX-1Start of three Phase II trials for IFX-1 in two serious inflammatory diseasesExpansion of our...
InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum
February 27, 2019 08:30 ET
|
InflaRx N.V.
Third autoimmune disease being evaluated with IFX-1 Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful ulcers JENA, Germany, Feb. 27, 2019 (GLOBE NEWSWIRE) --...
Richard Brudnick to Join InflaRx Board of Directors
February 14, 2019 08:30 ET
|
InflaRx N.V.
JENA, Germany, Feb. 14, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
February 06, 2019 07:00 ET
|
InflaRx N.V.
Retrospective long-term results from phase IIa trial indicate sustained remission post IFX-1 treatmentBaseline characteristics from ongoing phase IIb SHINE trial in line with expectations; on track...
InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management
January 03, 2019 08:30 ET
|
InflaRx N.V.
Jason Marks appointed Chief Legal Officer / General CounselJordan Silverstein appointed Head of Corporate Strategy / Development JENA, Germany and NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) --...
InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis
December 19, 2018 08:30 ET
|
InflaRx N.V.
JENA, Germany, Dec. 19, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting...
InflaRx N.V. Reports Third Quarter 2018 Financial & Operating Results
November 21, 2018 08:30 ET
|
InflaRx N.V.
Completion of patient recruitment in phase IIb trial in Hidradenitis SuppurativaFirst patient dosed in phase II trial with IFX-1 in ANCA-associated vasculitis Board of Directors appointment Jens...
InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa
November 08, 2018 02:30 ET
|
InflaRx N.V.
Trial Results Anticipated First Half 2019 JENA, Germany, Nov. 08, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq:IFRX), a biopharmaceutical company developing innovative therapeutics to treat...
InflaRx Initiates Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis with First Patient Dosing
October 30, 2018 07:30 ET
|
InflaRx N.V.
JENA, Germany, Oct. 30, 2018 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases by targeting...